This opportunity uses the U01 Research Project – Cooperative Agreements funding mechanism.
The goal of this scheme is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer’s disease (AD), slow its progression, or treat its cognitive and behavioural symptoms.
Funding & Duration
Application budgets are limited to USD $1M (approx. AUD $1.32M) in direct costs per year, and need to reflect the actual needs of the proposed project.
For Early Stage projects, the project period is limited to five years. For Late Stage projects, the project period is limited to three years.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Submission Requirements & Due Date
- Applications must be submitted for internal review by 21 September 2018
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review